Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial Key Points Question Does izalontamab brengitecan improve progression-free survival (PFS) and overall survival compared with chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma who progressed after first-line programmed cell death 1 protein/programmed cell death 1 ligand 1 inhibitor plus platinum-containing chemotherapy?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.